NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS
申请人:Bartkovitz David Joseph
公开号:US20110086854A1
公开(公告)日:2011-04-14
There are provided compounds of the formula
wherein X, Y, R
1
, R
2
, R
3
, R
3
, R
4
, and R
5
are as described herein
and enantiomers and pharmaceutically acceptable salts and esters thereof which are useful as anticancer agents.
There are provided compounds of the formula
wherein X, Y, R
1
, R
2
, R
3
, R
3
, R
4
, R
5
, R
6
and R
7
are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
There are provided compounds of formula I
or a pharmaceutically acceptable salt thereof,
wherein X, Y, R
1
, R
1′
, R
2
, R
2′
, R
3
, R
4
, R
5
are as defined herein. The compounds exhibit activity as anticancer agents.
There is provided a compound of the formula
wherein
X, Y, W, R
1
, R
2
and R
3
are as described herein. The compounds have activity as anticancer agents.
Compounds of formula
and enantiomers and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control, amelioration or prevention of cancer.